Marksans Pharma reported a consolidated net profit of ₹1,594.07 million for the quarter ended June 30, 2026, a 174% increase from ₹582.02 million in the corresponding quarter of the previous year. This sharp rise in profitability underscores strong operational performance and favorable foreign exchange impacts during the period. Consolidated revenue from operations reached ₹8,407.96 million, up 36% year-on-year from ₹6,199.89 million, driven by growth across its global pharmaceutical segments. The Board of Directors approved these unaudited financial results at a meeting held on August 12, 2026.

The statutory auditors, M/s. MSKA & Associates LLP, submitted limited review reports for both standalone and consolidated financial results with an unmodified opinion, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were prepared in accordance with Indian Accounting Standard 34 'Interim Financial Reporting'.

Financial Performance

The company’s total income rose to ₹8,662.00 million from ₹6,256.30 million in Q1FY25. Total expenses increased to ₹6,596.29 million from ₹5,490.32 million, primarily due to higher cost of materials consumed (₹2,206.69 million vs ₹1,926.94 million) and employee benefits expense (₹1,142.94 million vs ₹983.85 million). Profit before tax climbed to ₹2,065.71 million from ₹765.98 million. Total tax expense was ₹471.64 million, compared to ₹183.96 million in the prior year quarter.

Standalone net profit was ₹690.37 million, down from ₹919.23 million in Q4FY26 but significantly higher than the ₹480.56 million reported in Q1FY25. Standalone revenue declined to ₹3,211.87 million from ₹3,615.73 million in the preceding quarter.

Strategic Acquisitions and Other Developments

During the quarter, Marksans Pharma acquired 100% of the share capital of QliniQ B.V., a Netherlands-based healthcare solutions provider, for a consideration of EUR 7.50 Million. QliniQ B.V. became a wholly owned subsidiary effective April 1, 2026. Subsequent to the quarter-end, the company completed the acquisition of ABCnow GmbH, a Germany-based pharmaceutical firm with frontend sales and distribution capabilities, for EUR 1.10 Million.

Additionally, the company granted 300,000 stock options under the Marksans Employees Stock Option Scheme 2024 to eligible employees. Each option is exercisable into one equity share with a face value of ₹1.

What the Numbers Show

A significant portion of the income growth stems from other income, which includes a net gain on foreign exchange differences of ₹120.01 million in the consolidated results. This compares to a net loss of ₹38.93 million in Q1FY25, indicating that currency fluctuations contributed materially to the bottom-line improvement. While operational revenues grew robustly, the reversal in forex losses highlights the sensitivity of the company's international operations to currency movements.

Marksans Pharma reported an all-time high quarterly EBITDA of ₹213 crore and a net profit (PAT) of ₹159 crore for Q1FY27, driven by a 74.7% year-on-year revenue surge in the UK and Europe region. Consolidated revenue from operations rose 35.6% to ₹841 crore in the quarter ended June 30, 2026, reflecting strong underlying growth of 28.5% even after excluding ₹44 crore contributed by its recent acquisition, QliniQ B.V. The company also crossed a cash balance milestone of ₹1,058 crore, demonstrating robust liquidity despite recent inorganic expansions.

The Board of Directors approved the unaudited financial results on August 12, 2026. M/s. MSKA & Associates LLP, the statutory auditors, issued an unmodified limited review report pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were prepared in accordance with Indian Accounting Standard 34 (Ind AS 34). India Ratings and Research (Fitch Group) revised the outlook on the company’s bank loan facilities to Positive from Stable, while affirming ratings at IND AA-/IND A1+.

Financial Performance

Consolidated revenue grew to ₹8,407.96 million in Q1FY27 from ₹6,199.89 million in the corresponding period last year. Gross profit expanded by 38.9% to reflect improved product mix and lower-cost materials, pushing gross margins up by 138 basis points to 59.1%. Operating leverage further boosted profitability, as costs below gross profit grew only 10.2% against the 35.6% revenue increase, expanding EBITDA margins by 919 basis points to 25.3%.

Net profit after tax rose 173.9% to ₹1,594.07 million, aided by a lower effective tax rate of 22.8%. Other income included net gains from foreign exchange differences. Sequentially, revenue remained stable, with growth in the UK and Europe offsetting seasonal softness in Australia, New Zealand, and the US. Cash generated from operations stood at ₹185 crore, with net capex of ₹33 crore resulting in free cash flow of ₹152 crore.

Regional Highlights

The UK and Europe segment delivered its highest-ever quarterly revenue of ₹356 crore, growing 74.7% year-on-year. Excluding the contribution from QliniQ B.V., organic growth in the region stood at 53.1%. The US market saw single-digit price erosion in prescription products but maintained a healthy order book for new launches, contributing ₹377 crore or ~45% of consolidated revenue. Australia and New Zealand performance moderated sequentially following a strong fourth quarter, consistent with seasonal patterns, though it grew 53.7% year-on-year to ₹88 crore. Rest of World (RoW) revenue declined 36.8% year-on-year to ₹20 crore but showed its first sequential improvement in four quarters, up 6.0% quarter-on-quarter.

Strategic Expansions

During the quarter, Marksans Pharma consolidated its acquisition of QliniQ B.V., which contributed ₹44 crore in revenue. The company also completed the acquisition of ABCnow GmbH in Germany, with consolidation expected to commence in the next quarter. Additionally, Marksans Pharma (Europe) Ltd. was established in Ireland to handle EU filings and licensing, while Marksans (Canada) Inc. was incorporated with initial product approvals received. Research & development spends were ₹23 crore, representing 2.8% of consolidated revenue.

What the Numbers Show

The disproportionate expansion in EBITDA margin (919 bps) compared to revenue growth (35.6%) indicates significant operating leverage. This suggests that fixed costs are being spread over a larger revenue base more efficiently than in previous periods. Furthermore, the ability to maintain a cash balance above ₹1,000 crore while executing multiple acquisitions highlights disciplined capital allocation and strong operational cash generation. The improvement in working capital cycle to ~132 days from ~159 days in Q1FY26 further underscores enhanced operational efficiency.